PubMed Health⌕ Search

PubMed · 10936518

Micropropagation of Dev-ringal

Abstract

An efficient protocol for in vitro propagation of Thamnocalamus spathiflorus (Trin.) Munro, an evergreen temperate bamboo, through multiple shoot formation from zygotic embryos excised from germinating seeds, as well as from nodal explants taken from a 2-year-old plant has been developed. Multiple shoot formation was standardized in both the cases on Murashige and Skoog (MS) medium supplemented with 5.0 µM 6-benzylaminopurine (BAP) and 1.0 µM indole-3-butyric acid (IBA). Clumps of three to four microshoots when transferred to plant growth regulator-free medium following 14 days' initial culture on medium supplemented with 150.0 µM IBA, resulted in 100% rooting with five to 12 roots per rooted plant. Then, 18 months following the transfer of in vitro propagated plants into earthen pots containing soil and growth under outdoor conditions, gas and water vapour exchange rates were measured at different light levels (0, 100, 500, 1000, 1500, 2000 µmol(-2) s(-1)), and compared with seedlings of the same age. Light optima for photosynthesis were recorded approximately 1000 µmol m(-2) s(-1) in in vitro propagated plants as well as seedlings. Water use efficiency increased with increase in the light intensity up to 1000 µmol m(-2) s(-1) and then decreased subsequently at higher light intensities. Stomatal conductance and transpiration also increased with the increase in light intensity up to 2000 µmol(-2) s(-1). Intercellular CO(2) concentration (C(i)) and the ratio of intercellular CO(2) concentration to ambient CO(2) (C(i)/C(a)) decreased with the increase in light intensity up to 500 µmol(-2) s(-1) and then reached nearly constant levels at higher light intensities. The results show that in vitro propagated and hardened plants of T. spathiflorus are morphologically as well as functionally comparable to seed raised plants of the same age, within the limits of this study.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N Bag, S Chandra, LM Palni, SK Nandi. 2000-07-28. Micropropagation of Dev-ringal. https://doi.org/10.1016/s0168-9452(00)00212-0

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗